

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

TERMINATION OF THE 2026 A SHARE EMPLOYEE STOCK OWNERSHIP SCHEME

Reference is made to the announcement of the Company dated 27 April 2026 (“**Announcement**”) in relation to the adoption of the 2026 A Share Employee Stock Ownership Scheme. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

In order to better safeguard the interests of the Company, its shareholders, and its employees, after due consideration, the Board of Directors has resolved to terminate the 2026 A Share Employee Stock Ownership Scheme, the Administrative Measures for the 2026 A Share Employee Stock Ownership Scheme and all other ancillary documents accordingly.

The termination of 2026 A Share Employee Stock Ownership Scheme by the Company is made in accordance with the Guidance Opinions on the Pilot Implementation of Employee Stock Ownership Plan by Listed Companies* (《關於上市公司實施員工持股計劃試點的指導意見》), Guidelines No. 1 of Shanghai Stock Exchange for Self-Regulation of Listed Companies on the SSE STAR Market — Standardized Operations* (《上海證券交易所科創板上市公司自律監管指引第 1 號——規範運作》) and other applicable laws, regulations and normative documents. The termination of the 2026 A Share Employee Stock Ownership Scheme will not adversely affect the Company's development strategy or business plans, will not have an impact on the Company's financial condition or operating results, and does not involve any circumstances that would be detrimental to the interests of the Company or its shareholders as a whole.

Going forward, the Company will continue to refine its long-term incentive mechanisms in light of applicable laws and regulations, market conditions, and the Company's actual circumstances, so as to promote the sound and sustainable development of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 26 August 2026

As at the date of this announcement, the Board of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

* *For identification purpose only*